- Home
- ZENV vs PRLD Comparison
ZENV vs PRLD Comparison
Compare ZENV & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- PRLD
- Stock Information
- Founded
- ZENV 2005
- PRLD 2016
- Country
- ZENV Brazil
- PRLD United States
- Employees
- ZENV N/A
- PRLD N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- ZENV Technology
- PRLD Health Care
- Exchange
- ZENV Nasdaq
- PRLD Nasdaq
- Market Cap
- ZENV 70.8M
- PRLD 69.1M
- IPO Year
- ZENV 2021
- PRLD 2020
- Fundamental
- Price
- ZENV $1.35
- PRLD $1.59
- Analyst Decision
- ZENV
- PRLD Strong Buy
- Analyst Count
- ZENV 0
- PRLD 3
- Target Price
- ZENV N/A
- PRLD $4.00
- AVG Volume (30 Days)
- ZENV 27.2K
- PRLD 252.6K
- Earning Date
- ZENV 11-17-2025
- PRLD 10-31-2025
- Dividend Yield
- ZENV N/A
- PRLD N/A
- EPS Growth
- ZENV N/A
- PRLD N/A
- EPS
- ZENV N/A
- PRLD N/A
- Revenue
- ZENV $201,426,369.00
- PRLD $7,000,000.00
- Revenue This Year
- ZENV $6.49
- PRLD N/A
- Revenue Next Year
- ZENV $3.82
- PRLD N/A
- P/E Ratio
- ZENV N/A
- PRLD N/A
- Revenue Growth
- ZENV 24.80
- PRLD N/A
- 52 Week Low
- ZENV $1.02
- PRLD $0.61
- 52 Week High
- ZENV $3.03
- PRLD $1.91
- Technical
- Relative Strength Index (RSI)
- ZENV 44.84
- PRLD 60.06
- Support Level
- ZENV $1.29
- PRLD $1.47
- Resistance Level
- ZENV $1.41
- PRLD $1.72
- Average True Range (ATR)
- ZENV 0.06
- PRLD 0.16
- MACD
- ZENV -0.00
- PRLD 0.01
- Stochastic Oscillator
- ZENV 40.74
- PRLD 85.71
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.